2025年4月6日 周日
Home > Archive>Volume 31, Issue 4, 2023 >287-296. DOI:10.20039/j.cnki.10073949.2023.04.002
PDF HTML XML Export Cite reminder
Non-vascular diseases and atherosclerosis:the critical role of endothelial inflammation and oxidative stress
CSTR:
[cstr]
Author:
Affiliation:

1.Department of Pathophysiology, Shenzhen University Health Science Center, Shenzhen, Guangdong 518060, China;2.Department of Biomedical Sciences, City University of Hong Kong, Hong Kong 999077, China;3.Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, Guangdong 518057, China)

Clc Number:

R543.5

  • Article
    • | |
  • Metrics
    • |
  • Reference [70]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    Atherosclerosis (As) is a focal vascular disease that closely related to many injury factors such as endothelial inflammation, oxidative stress, and shear stress. More and more studies have shown that the risk of As is higher in a variety of non-cardiovascular diseases. This review summarizes the mechanism of As in respiratory system diseases, digestive system diseases, urinary and reproductive system diseases, autoimmune diseases and metabolic diseases from the perspective of endothelial inflammation and oxidative stress.

    Reference
    [1] JEBARI-BENSLAIMAN S, GALICIA-GARCA U, LARREA-SEBAL A, et al.Pathophysiology of atherosclerosis.Int J Mol Sci, 2,3(6):3346.
    [2] LIBBY P.The changing landscape of atherosclerosis.Nature, 1,2(7855):524-533.
    [3] HE L, ZHANG C L, CHEN Q H, et al.Endothelial shear stress signal transduction and atherogenesis:from mechanisms to therapeutics.Pharmacol Ther, 2,5:108152.
    [4] 董亚兰, 胡德胜.动脉粥样硬化的炎症应答特征及运用.中国动脉硬化杂志, 2,0(4):304-312.DONG Y L, HU D S.Characteristics and application of inflammatory response in atherosclerosis.Chin J Arterioscler, 2,0(4):304-312.
    [5] 肖素军, 赵明.动脉粥样硬化与免疫.中国动脉硬化杂志, 2,0(4):277-286.XIAO S J, ZHAO M.Atherosclerosis and immunity.Chin J Arterioscler, 2,0(4):277-286.
    [6] ENGELEN S E, ROBINSON A J B, ZURKE Y X, et al.Therapeutic strategies targeting inflammation and immunity in atherosclerosis:how to proceed?.Nat Rev Cardiol, 2,9(8):522-542.
    [7] LVY P, KOHLER M, MCNICHOLAS W T, et al.Obstructive sleep apnoea syndrome.Nat Rev Dis Primers, 5,1:15015.
    [8] LU M, FANG F, WANG Z, et al.Association between OSA and quantitative atherosclerotic plaque burden:a coronary CT angiography study.Chest, 1,0(5):1864-1874.
    [9] SONG D, FANG G, MAO S Z, et al.Selective inhibition of endothelial NF-κB signaling attenuates chronic intermittent hypoxia-induced atherosclerosis in mice.Atherosclerosis, 8,0:68-75.
    [10] LOFFREDO L, ZICARI A M, OCCASI F, et al.Endothelial dysfunction and oxidative stress in children with sleep disordered breathing:role of NADPH oxidase.Atherosclerosis, 5,0(1):222-227.
    [11] BIRONNEAU V, TAMISIER R, TRZEPIZUR W, et al.Sleep apnoea and endothelial dysfunction:an individual patient data Meta-analysis.Sleep Med Rev, 0,2:101309.
    [12] GOMEZ N, JAMES V, ONION D, et al.Extracellular vesicles and chronic obstructive pulmonary disease(COPD):a systematic review.Respir Res, 2,3(1):82.
    [13] FISK M, MCENIERY C M, GALE N, et al.Surrogate markers of cardiovascular risk and chronic obstructive pulmonary disease:a large case-controlled study.Hypertension, 8,1(3):499-506.
    [14] AMBROSINO P, LUPOLI R, CAFARO G, et al.Subclinical carotid atherosclerosis in patients with chronic obstructive pulmonary disease:a Meta-analysis of literature studies.Ann Med, 7,9(6):513-524.
    [15] HUANG D, SU L, HE C, et al.Pristimerin alleviates cigarette smoke-induced inflammation in chronic obstructive pulmonary disease via inhibiting NF-κB pathway.Biochem Cell Biol, 2,0(3):10.
    [16] SHEN Y, YANG T, GUO S, et al.Increased serum ox-LDL levels correlated with lung function, inflammation, and oxidative stress in COPD.Mediators Inflamm, 3,3:972347.
    [17] LONG B, BRADY W J, KOYFMAN A, et al.Cardiovascular complications in COVID-19.Am J Emerg Med, 0,8(7):1504-1507.
    [18] LIU Y, ZHANG H G.Vigilance on new-onset atherosclerosis following SARS-CoV-2 infection.Front Med(Lausanne), 0,7:629413.
    [19] SKENDROS P, MITSIOS A, CHRYSANTHOPOULOU A, et al.Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.J Clin Invest, 0,0(11):6151-6157.
    [20] ZHANG L, LI M, WANG Z, et al.Cardiovascular risk after SARS-CoV-2 infection is mediated by IL18/IL18R1/HIF-1 signaling pathway axis.Front Immunol, 1,2:780804.
    [21] GAO P Y, ZHOU W, HUANG P N, et al.Persistent endothelial dysfunction in coronavirus disease-2019 survivors late after recovery.Front Med(Lausanne), 2,9:809033.
    [22] KNOFLACH M, KIECHL S, MAYR A, et al.Allergic rhinitis, asthma, and atherosclerosis in the bruneck and ARMY studies.Arch Intern Med, 5,5(21):2521-2526.
    [23] LIU L C, WANG Y, LIAO M, et al.Allergic lung inflammation promotes atherosclerosis in apolipoprotein E-deficient mice.Transl Res, 6,1:1-16.
    [24] WANG J, CHENG X, XIANG M X, et al.IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in ApoE－/－ mice.J Clin Invest, 1,1(9):3564-3577.
    [25] WANG L, GAO S, XU W, et al.Allergic asthma accelerates atherosclerosis dependent on Th2 and Th17 in apolipoprotein E deficient mice.J Mol Cell Cardiol, 4,2:20-27.
    [26] GAO S, ZHANG W, ZHAO Q, et al.Curcumin ameliorates atherosclerosis in apolipoprotein E deficient asthmatic mice by regulating the balance of Th2/Treg cells.Phytomedicine, 9,2:129-135.
    [27] ZHU J, QUYYUMI A A, NORMAN J E, et al.The possible role of hepatitis A virus in the pathogenesis of atherosclerosis.J Infect Dis, 0,2(6):1583-1587.
    [28] AUER J, LEITINGER M, BERENT R, et al.Hepatitis A IgG seropositivity and coronary atherosclerosis assessed by angiography.Int J Cardiol, 3,0(2/3):175-179.
    [29] RIVEIRO-BARCIELA R M, MARCOS-FOSCH C, Martinez-Valle F, et al.Nave hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis:a prospective study.World J Gastroenterol, 1,7(30):5112-5125.
    [30] WANG C H, CHEN C J, LEE M H, et al.Chronic hepatitis B infection and risk of atherosclerosis-related mortality:a 17-year follow-up study based on 22 472 residents in Taiwan.Atherosclerosis, 0,1(2):624-629.
    [31] TOMIYAMA H, ARAI T, HIROSE K, et al.Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity.Atherosclerosis, 3,6(2):401-403.
    [32] MUOZ-HERNNDEZ R, AMPUERO J, MILLN R, et al.Hepatitis C virus clearance by direct-acting antivirals agents improves endothelial dysfunction and subclinical atherosclerosis:HEPCAR study.Clin Transl Gastroenterol, 0,1(8):e00203.
    [33] TANG A S P, CHAN K E, QUEK J, et al.Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke:an updated Meta-analysis with 135 602 individuals.Clin Mol Hepatol, 2,8(3):483-496.
    [34] PANG Q, SUN Z, SHAO C, et al.CML/RAGE signal bridges a common pathogenesis between atherosclerosis and non-alcoholic fatty liver.Front Med(Lausanne), 0,7:583943.
    [35] CHATRATH H, VUPPALANCHI R, CHALASANI N, et al.Dyslipidemia in patients with nonalcoholic fatty liver disease.Semin Liver Dis, 2,2(1):22-29.
    [36] FADAEI R, POUSTCHI H, MESHKANI R, et al.Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis.Sci Rep, 8,8(1):11691.
    [37] PRIVITERA G, SPADARO L, ALAGONA C, et al.Hepatic insulin resistance in NAFLD:relationship with markers of atherosclerosis and metabolic syndrome components.Acta Diabetol, 6,3(3):449-459.
    [38] SHI H, LI Y, DONG C, et al.Helicobacter pylori infection and the progression of atherosclerosis:a systematic review and Meta-analysis.Helicobacter, 2,7(1):e12865.
    [39] LI N, LIU S F, DONG K, et al.Exosome-transmitted miR-25 induced by H.pylori promotes vascular endothelial cell injury by targeting KLF2.Front Cell Infect Microbiol, 9,9:366.
    [40] XIA X, ZHANG L, WU H, et al.CagA+ helicobacter pylori, not CagA－ helicobacter pylori, infection impairs endothelial function through exosomes-mediated ROS formation.Front Cardiovasc Med, 2,9:881372.
    [41] DUAN J, WANG C, LIU D, et al.Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in Chinese rural residents:a cross-sectional survey.Sci Rep, 9,9(1):10408.
    [42] BAJAJ A, XIE D, CEDILLO-COUVERT E, et al.Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD.Am J Kidney Dis, 9,3(6):827-836.
    [43] WAKAMATSU T, YAMAMOTO S, ITO T, et al.Indoxyl sulfate promotes macrophage IL-1β production by activating aryl hydrocarbon receptor/NF-κ/MAPK cascades, but the NLRP3 inflammasome was not activated.Toxins (Basel), 8,0(3):124.
    [44] NAKANO T, KATSUKI S, CHEN M, et al.Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation via the interplay of OATP2B1 and Dll4-Notch signaling.Circulation, 9,9(1):78-96.
    [45] KIM H Y, YOO T H, HWANG Y, et al.Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease(ESRD).Sci Rep, 7,7(1):3057.
    [46] DOU L, JOURDE-CHICHE N, FAURE V, et al.The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells.J Thromb Haemost, 7,5(6):1302-1308.
    [47] SUN D, WU Y, DING M, et al.Comprehensive Meta-analysis of functional and structural markers of subclinical atherosclerosis in women with polycystic ovary syndrome.Angiology, 2,3(7):622-634.
    [48] FENKCI V, FENKCI S, YILMAZER M, et al.Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease.Fertil Steril, 3,0(1):123-127.
    [49] CALZADA M, LPEZ N, NOGUERA J A, et al.Elevation of isoprostanes in polycystic ovary syndrome and its relationship with cardiovascular risk factors.J Endocrinol Invest, 9,2(1):75-83.
    [50] PERTYNSKA-MARCZEWSKA M, DIAMANTI-KANDARAKIS E, ZHANG J, et al.Advanced glycation end products:a link between metabolic and endothelial dysfunction in polycystic ovary syndrome?.Metabolism, 5,4(11):1564-1573.
    [51] PARADISI G, STEINBERG H O, HEMPFLING A, et al.Polycystic ovary syndrome is associated with endothelial dysfunction.Circulation, 1,3(10):1410-1415.
    [52] SKEOCH S, CRISTINACCE P L H, WILLIAMS H, et al.Imaging atherosclerosis in rheumatoid arthritis:evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation.Sci Rep, 7,7(1):827.
    [53] AMBROSINO P, LUPOLI R, DI MINNO A, et al.Subclinical atherosclerosis in patients with rheumatoid arthritis:a Meta-analysis of literature studies.Thromb Haemost, 5,3(5):916-930.
    [54] MAHTTA D, GUPTA A, RAMSEY D J, et al.Autoimmune rheumatic diseases and premature atherosclerotic cardiovascular disease:an analysis from the vital registry.Am J Med, 0,3(12):1424-1432.
    [55] SATTAR N, MCCAREY D W, CAPELL H, et al.Explaining how “High-Grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis.Circulation, 3,8(24):2957-2963.
    [56] SAHA A, BAGCHI A, CHATTERJEE S, et al.Phenotypic characterization of circulating endothelial cells induced by inflammation and oxidative stress in ankylosing spondylitis.Free Radic Res, 1,5(5):520-532.
    [57] YUAN Y, YANG J, ZHANG X, et al.Carotid intima-media thickness in patients with ankylosing spondylitis:a systematic review and updated Meta-analysis.J Atheroscler Thromb, 9,6(3):260-271.
    [58] LU X, WANG Y, ZHANG J, et al.Patients with systemic lupus erythematosus face a high risk of cardiovascular disease:a systematic review and Meta-analysis.Int Immunopharmacol, 2021:107466.
    [59] XU W D, SU L C, XIE Q B, et al.Interleukin-2-inducible T-cell kinase expression and relation to disease severity in systemic lupus erythematosus.Clin Chim Acta, 6,3:11-17.
    [60] MARCZYNSKI P, MEINECK M, XIA N, et al.Vascular inflammation and dysfunction in lupus-prone mice-IL-6 as mediator of disease initiation.Int J Mol Sci, 1,2(5):2291.
    [61] GAL K, TARR T, LRINCZ H, et al.High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus.Lipids Health Dis, 2016:60.
    [62] SMITH C K, SETO N L, VIVEKANANDAN-GIRI A, et al.Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity.Ann Rheum Dis, 7,6(3):602-611.
    [63] MCMAHON M, GROSSMAN J, SKAGGS B, et al.Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.Arthritis Rheum, 9,0(8):2428-2437.
    [64] SANDFORT V, LAI S, AHLMAN M A, et al.Obesity is associated with progression of atherosclerosis during statin treatment.J Am Heart Assoc, 6,5(7):e003621.
    [65] KATSIKI N, MANTZOROS C, MIKHAILIDIS D P, et al.Lipids and atherosclerosis.Curr Opin Lipidol, 7,8(4):347-354.
    [66] MELGAR-LESMES P, SNCHEZ-HERRERO A, LOZANO-JUAN F, et al.Chondroitin sulphate attenuates atherosclerosis in ApoE knockout mice involving cellular regulation of the inflammatory response.Thromb Haemost, 8,8(7):1329-1339.
    [67] YESILBURSA D, SERDAR Z, SERDAR A, et al.Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels.Int J Obes (Lond), 5,9(1):142-145.
    [68] SHARMA A, CHOI J S Y, STEFANOVIC N, et al.Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis.Diabetes, 1,0(3):772-787.
    [69] AZEMI A K, MOKHTAR S S, SHARIF S E T, et al.Clinacanthus nutans attenuates atherosclerosis progression in rats with type 2 diabetes by reducing vascular oxidative stress and inflammation.Pharm Biol, 1,9(1):1432-1440.
    [70] MENG Z, LIANG H, ZHAO J, et al.HMOX1 upregulation promotes ferroptosis in diabetic atherosclerosis.Life Sci, 2021:119935.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

WANG Mengyan, LIU Jie, HUANG Yu, ZHANG Chenglin. Non-vascular diseases and atherosclerosis:the critical role of endothelial inflammation and oxidative stress[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2023,31(4):287-296.

Copy
Share
Article Metrics
  • Abstract:1389
  • PDF: 1753
  • HTML: 0
  • Cited by: 0
History
  • Received:July 28,2022
  • Revised:September 28,2022
  • Online: April 06,2023
Article QR Code

You are the 27926 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025